Performance of RYTM Rhythm Pharmaceuticals | 107.6% in 12m
Compare RYTM with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Rhythm Pharmaceuticals with its related Sector/Index XBI
Performance Duell RYTM vs XBI
| TimeFrame | RYTM | XBI |
|---|---|---|
| 1 Week | 13.5% | 2.09% |
| 1 Month | 19.2% | 4.45% |
| 3 Months | 27.8% | 7.71% |
| 6 Months | 28.2% | 11.24% |
| 12 Months | 107.6% | 44.21% |
| YTD | 24.6% | 11.67% |
| Rel. Perf. 1m | 0.76 | |
| Rel. Perf. 3m | 1.20 | |
| Rel. Perf. 6m | 1.82 | |
| Rel. Perf. 12m | 3.50 | |
| Spearman 1m | 0.18 | 0.236 |
| Spearman 3m | 0.58 | -0.066 |
Is Rhythm Pharmaceuticals a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Rhythm Pharmaceuticals is currently (November 2024)
neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -20.43 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RYTM as of November 2024 is 61.27. This means that RYTM is currently overvalued and has a potential downside of 8.92% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RYTM as of November 2024 is 61.27. This means that RYTM is currently overvalued and has a potential downside of 8.92% (Sold with Premium).
Is RYTM a buy, sell or hold?
- Strong Buy: 4
- Buy: 5
- Hold: 1
- Sell: 0
- Strong Sell: 0
Values above 0%: RYTM is performing better - Values below 0%: RYTM is underperforming
Compare RYTM with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 14.41% | 17.60% | 15.85% | 73.49% |
| US NASDAQ 100 | QQQ | 15.13% | 17.07% | 16.05% | 73.41% |
| US Dow Jones Industrial 30 | DIA | 9.87% | 14.93% | 14.69% | 77.15% |
| German DAX 40 | DAX | 15.24% | 20.76% | 24.15% | 82.09% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 11.32% | 39.97% | 16.93% | 94.30% |
| Hongkong Hang Seng | HSI | 11.82% | 28.85% | 17.74% | 98.24% |
| India NIFTY 50 | INDA | 14.43% | 21.52% | 23.65% | 83.74% |
| Brasil Bovespa | EWZ | 13.97% | 23.04% | 38.44% | 113.80% |
RYTM Rhythm Pharmaceuticals vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 12.65% | 15.32% | 13.01% | 67.95% |
| Consumer Discretionary | XLY | 12.19% | 15.15% | 14.86% | 80.10% |
| Consumer Staples | XLP | 12.96% | 18.90% | 20.28% | 86.88% |
| Energy | XLE | 10.89% | 22.74% | 29.96% | 98.80% |
| Financial | XLF | 13.99% | 15.58% | 13.59% | 66.68% |
| Health Care | XLV | 13.91% | 21.24% | 22.83% | 90.54% |
| Industrial | XLI | 13.19% | 18.49% | 17.71% | 71.27% |
| Materials | XLB | 14.02% | 20.45% | 23.22% | 85.76% |
| Real Estate | XLRE | 13.54% | 17.76% | 7.84% | 76.70% |
| Technology | XLK | 16.30% | 17.76% | 17.08% | 75.43% |
| Utilities | XLU | 14.70% | 20.53% | 12.53% | 76.46% |
| Aerospace & Defense | XAR | 14.64% | 20.15% | 16.93% | 75.93% |
| Biotech | XBI | 11.45% | 14.72% | 16.95% | 63.43% |
| Homebuilder | XHB | 10.64% | 21.41% | 16.92% | 51.53% |
| Retail | XRT | 11.47% | 16.58% | 23.48% | 80.44% |
Does Rhythm Pharmaceuticals outperform its market, is RYTM a Sector Leader?
Yes, over the last 12 months Rhythm Pharmaceuticals (RYTM) made 107.64%, while its related Sector, the SPDR S&P Biotech (XBI) made 44.21%.
Over the last 3 months RYTM made 27.75%, while XBI made 7.71%.
Yes, over the last 12 months Rhythm Pharmaceuticals (RYTM) made 107.64%, while its related Sector, the SPDR S&P Biotech (XBI) made 44.21%.
Over the last 3 months RYTM made 27.75%, while XBI made 7.71%.
| Period | RYTM | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 19.17% | 4.45% | 1.57% |
| 3 Months | 27.75% | 7.71% | 11.81% |
| 12 Months | 107.64% | 44.21% | 34.15% |